Eovist® (gadoxetate disodium) Injection Coding Tip Sheet

Hospital-based Outpatient Radiology Departments

Billing for Eovist

Eovist has been assigned a unique Healthcare Common Procedure Coding System (HCPCS) code. A9581 should be used for all claims.[1]

HCPCS Code for Use with Eovist

HCPCS code	A9581
Code description	Injection, gadoxetate disodium, 1 mL
Possible revenue code	636

- When billing for Eovist for services:
  - Enter the A9581 code in record locator 44 on the Centers for Medicare and Medicaid Services (CMS) 1450 Form
  - If appropriate, bill for a quantity of 10 units in record locator 46 to reflect the total mL dosage

Beginning January 1, 2011, Eovist is no longer eligible to receive pass-through payments from Medicare. Transitional pass-through status is effective for two to three years only. The current Medicare payment methodology for contrast agents in the hospital outpatient setting packages payment for the contrast material into payment for the imaging procedure. Separate payment for Eovist will no longer be made outside of that packaged rate.

CMS does encourage hospitals to continue to bill for all contrast agents used in order to collect claims data to determine appropriate reimbursement. Facilities are instructed to bill for Eovist using its unique HCPCS code, A9581.

Indication and Usage

Eovist® (gadoxetate disodium) injection is indicated for intravenous use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.

Important Safety Information

WARNING: NEPHROGENIC SYSTEM FIBROSIS (NSF)

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

- The risk for NSF appears highest among patients with:
  - Chronic, severe kidney disease (GFR <30 mL/min/1.73m^2), or
  - Acute kidney injury
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
- For patients at highest risk for NSF, do not exceed the recommended Eovist® dose and allow a sufficient period of time for eliminating of the drug from the body prior to any re-administration.

Please see additional Important Safety Information throughout this piece.

Please click here to see the Eovist® Full Prescribing Information.

Learn more about Eovist at eovist.com

Eovist®
(gadoxetate disodium) injection
0.25 mmol/mL

Your Chargemaster and Eovist® (gadoxetate disodium) injection

The following information should be added to the hospital's chargemaster for the billing of Eovist:

- **Product name:** Eovist® (gadoxetate disodium) injection
- **Price per mL**
- **A9581**
- **Appropriate revenue code unique to your hospital's contrast expense:**
  - 636 (Drugs requiring detailed coding)

Reimbursement for Contrast by Payer

Medicare: Currently, Medicare packages payment for all diagnostic imaging contrast agents into the payment amount for the procedure in the hospital outpatient setting. Please consult the Reimbursement Helpline for guidance.[2]

Private Commercial: Some managed care organizations reimburse separately for contrast when billed with a procedure. Please consult the Reimbursement Helpline for guidance.

The Bayer Imaging Reimbursement Helpline is available to all institutions to provide further information on Eovist coverage reimbursement.

The Helpline can be reached at 800-423-7539 or via email at imaging@prgweb.com.

Information provided in this resource is for informational purpose only and does not guarantee that codes will be appropriate or that coverage and reimbursement will result. Customers should consult with their payers for all relevant coverage, coding, and reimbursement requirements. It is the sole responsibility of the provider to select proper codes and ensure the accuracy of all claims used in seeking reimbursement. Neither this resource nor the Bayer Healthcare Medical Care Reimbursement Helpline is intended as a legal advice or as a substitute for a provider's independent professional judgment.

Important Safety Information (continued)

Contraindication and Important Information about Hypersensitivity Reactions: Eovist® is contraindicated in patients with history of severe hypersensitivity reactions to Eovist®. Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have uncommonly occurred following Eovist® administration. Before Eovist® administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to Eovist®.

Acute Kidney Injury: In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of some GBCAs. The risk of acute kidney injury might be lower with Eovist® due to its dual excretory pathways. Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses.

Extravasation and Injection Site Reactions: Ensure catheter and venous patency before the injection of Eovist®. Extravasation into tissues during Eovist® administration may result in local tissue reactions. Strictly avoid intramuscular administration of Eovist® because it may cause myocyte necrosis and inflammation.

Please see additional Important Safety Information throughout this piece.

Please click here to see the Eovist® Full Prescribing Information.

Learn more about Eovist at eovist.com

Eovist®
(gadoxetate disodium) injection
0.25 mmol/mL

Claim Form Guidance

To help demonstrate billing of Eovist® (gadoxetate disodium) injection, the sample claim below is provided:



* Information provided in this resource is for informational purpose only and does not guarantee that codes will be appropriate or that coverage and reimbursement will result. Customers should consult with their payers for all relevant coverage, coding, and reimbursement requirements. It is the sole responsibility of the provider to select proper codes and ensure the accuracy of all claims used in seeking reimbursement. Neither this resource nor the Bayer Healthcare Medical Care Reimbursement Helpline is intended as a legal advice or as a substitute for a provider's independent professional judgment.

Reference: 1. http://www.cms.hhs.gov/hcpcsreleasecodesets/anhcpcs/List.asp. Accessed 5/01/2015.
2. 2011 Medicare Hospital Outpatient Prospective Payment System Final Rule.

Important Safety Information (continued)

Interference with Laboratory Tests: Serum iron determination using complexometric methods (for example, ferrocene complexation method) may result in falsely high or low values for up to 24 hours after the examination with Eovist® because of the caloxetate trisodium excipients.

Interference with Visualization of Liver Lesions: Severe renal or hepatic failure may impair Eovist® imaging performance. In patients with end-stage renal failure, hepatic contrast was markedly reduced and was attributed to elevated serum ferritin levels. In patients with abnormally high (>3 mg/dL) serum bilirubin, reduced hepatic contrast was observed. If Eovist® is used in these patients, complete MRI no later than 60 minutes after Eovist® administration and use a paired non-contrast and contrast MRI set for diagnosis.

Adverse Reactions: The most frequent (≥0.5%) adverse reactions associated with Eovist® are nausea (1.1%), headache (1.1%), feeling hot (0.8%), dizziness (0.6%), and back pain (0.6%).

Please see additional Important Safety Information throughout this piece.

Please click here to see the Eovist® Full Prescribing Information.

Learn more about Eovist at eovist.com

Bayer HealthCare

Radiology
Bayer HealthCare Medical Care
Bayer HealthCare LLC
100 Bayer Boulevard
P.O. Box 915
Whippany, NJ 07981
www.radiologysolutions.bayer.com

PP-320-US-0039 June 2015